Two Phase 3 Trials of Baricitinib for Alopecia Areata
Two Phase 3 Trials of Baricitinib for Alopecia Areata
About this item
Full title
Author / Creator
BRAVE-AA Investigators , King, Brett , Ohyama, Manabu , Kwon, Ohsang , Zlotogorski, Abraham , Ko, Justin , Mesinkovska, Natasha A , Hordinsky, Maria , Dutronc, Yves , Wu, Wen-Shuo , McCollam, Jill , Chiasserini, Chiara , Yu, Guanglei , Stanley, Sarah , Holzwarth, Katrin , DeLozier, Amy M and Sinclair, Rodney
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Alopecia areata is a distressing disorder of hair loss that is mediated partly by cytokines dependent on Janus kinases. The JAK1 and JAK2 inhibitor baricitinib reduced the extent of hair loss in two randomized trials over a period of 36 weeks.
Alternative Titles
Full title
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2659687153
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2659687153
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2110343
